AR078750A1 - Composicion farmaceutica para la administracion oral - Google Patents

Composicion farmaceutica para la administracion oral

Info

Publication number
AR078750A1
AR078750A1 ARP100103894A ARP100103894A AR078750A1 AR 078750 A1 AR078750 A1 AR 078750A1 AR P100103894 A ARP100103894 A AR P100103894A AR P100103894 A ARP100103894 A AR P100103894A AR 078750 A1 AR078750 A1 AR 078750A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
solid pharmaceutical
benzothien
glucitol
ylmethyl
Prior art date
Application number
ARP100103894A
Other languages
English (en)
Inventor
Tetsuya Tamura
Kazuhiro Sako
Keisuke Sakaura
Yoshifumi Katakawa
Original Assignee
Astellas Pharma Inc
Kotobuki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43900414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078750(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc, Kotobuki Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of AR078750A1 publication Critical patent/AR078750A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

La presente proporciona una composicion farmacéutica solida que comprende un cocristal de (1S)-1,5-anhidro-1-[3-(1-benzotien-2-ilmetil)-4-fluorofenil]-D-glucitol y L-prolina, en combinacion con la celulosa cristalina, y también proporciona un método para producir la composicion. Composicion util para tratar la diabetes. Reivindicacion 2: La composicion farmacéutica solida de acuerdo con la reivindicacion 1, en donde el contenido de la celulosa cristalina en la composicion farmacéutica es 5% en peso o más a 90% en peso o menos. Reivindicacion 4: La composicion farmacéutica solida de acuerdo con la reivindicacion 3, en donde el desintegrante es uno o más miembros seleccionados del grupo que consiste de glicolato de almidon sádico, y la hidroxipropilcelulosa cuyo contendido del grupo hidroxipropoxilo es 5% en peso o más a menos del 16% en peso. Reivindicacion 6: La composicion farmacéutica solida de acuerdo con cualquiera de las reivindicaciones 1 a 5, en donde el 65% o más de (1S)-1,5-anhidro-1-[3-(1-benzotien- 2-ilmetil)-4-fluorofenil]-D-glucitol se disuelve en 30 minutos, segun se analiza por la prueba de disolucion descrita en la Farmacopea Japonesa 15a revision. Reivindicacion 7: Un método para producir una composicion farmacéutica solida, que comprende las etapas de: (1) mezcla de un cocristal de (1S)-1,5-anhidro-1-[3-(1-benzotien-2-ilmetil)-4-fluorofenil]-D-glucitol y la L-prolina con la celulosa cristalina; y (2) granulacion de la mezcla resultante mediante granulacion humeda mientras que se conserva con la estructura cocristal entre (1S)-1,5-anhidro-1-[3-(1-benzotien-2-ilmetil)-4-fluorofenil]-D-glucitol y la L-prolina.
ARP100103894A 2009-10-23 2010-10-22 Composicion farmaceutica para la administracion oral AR078750A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25444309P 2009-10-23 2009-10-23

Publications (1)

Publication Number Publication Date
AR078750A1 true AR078750A1 (es) 2011-11-30

Family

ID=43900414

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103894A AR078750A1 (es) 2009-10-23 2010-10-22 Composicion farmaceutica para la administracion oral

Country Status (11)

Country Link
US (1) US20120214753A1 (es)
EP (1) EP2491933A1 (es)
JP (1) JP4759102B2 (es)
KR (1) KR101476011B1 (es)
CN (1) CN102596206B (es)
AR (1) AR078750A1 (es)
BR (1) BR112012007364A2 (es)
CA (1) CA2778411A1 (es)
MX (1) MX2012004782A (es)
RU (1) RU2012121183A (es)
WO (1) WO2011049191A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101841087B1 (ko) 2011-04-22 2018-03-23 아스텔라스세이야쿠 가부시키가이샤 고형 의약 조성물
CN106924206A (zh) * 2015-12-31 2017-07-07 深圳翰宇药业股份有限公司 一种依格列净口服固体制剂及其制备方法
WO2019030158A1 (en) * 2017-08-07 2019-02-14 Enantia, S.L. CO-CRYSTAL OF 2 - [(1R, 6R) -6-ISOPROPENYL-3-METHYLCYCLOHEX-2-EN-1-YL] -5-PENTYLBENZENE-1,3-DIOL
US20190177258A1 (en) * 2017-12-11 2019-06-13 Artelo Biosciences, Inc. New solid forms of cannabidiol and uses thereof
BR112021004839A2 (pt) * 2018-09-26 2021-06-08 Lexicon Pharmaceuticals, Inc. formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852336B2 (en) * 1995-11-15 2005-02-08 J. Rettenmaier & Soehne Gmbh + Co. Kg Directly compressible high load acetaminophen formulations
MXPA05009356A (es) * 2003-03-14 2005-12-05 Astellas Pharma Inc Derivados de c-glicosido y sales de los mismos.
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20090603A1 (es) * 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
WO2009096455A1 (ja) * 2008-01-31 2009-08-06 Astellas Pharma Inc. 脂肪性肝疾患の治療用医薬組成物

Also Published As

Publication number Publication date
BR112012007364A2 (pt) 2017-06-06
CN102596206B (zh) 2014-06-04
JP4759102B2 (ja) 2011-08-31
JPWO2011049191A1 (ja) 2013-03-14
KR20120127387A (ko) 2012-11-21
KR101476011B1 (ko) 2014-12-23
US20120214753A1 (en) 2012-08-23
EP2491933A1 (en) 2012-08-29
WO2011049191A1 (ja) 2011-04-28
CA2778411A1 (en) 2011-04-28
MX2012004782A (es) 2012-09-12
CN102596206A (zh) 2012-07-18
RU2012121183A (ru) 2013-11-27

Similar Documents

Publication Publication Date Title
AR078750A1 (es) Composicion farmaceutica para la administracion oral
ECSP066375A (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
EA200970090A1 (ru) Модуляторы метаболизма и лечение связанных с ним расстройств
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
PE20090015A1 (es) Preparacion solida
CO6361915A2 (es) Composición farmacéutica sólida que comprende amlodipina y losartan
EA200970088A1 (ru) Модуляторы метаболизма и лечение связанных с ним нарушений
ATE465719T1 (de) Oral zerfallende zusammensetzung von olanzapin oder donepezil
PE20110841A1 (es) FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
ECSP088281A (es) Moduladores del metabolismo y tratamiento de los trastornos metabólicos
NO20084318L (no) Inhibitorer av II-beta-hydroksystereoid dehydrogenase I
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
AR084832A1 (es) Derivado cristalino de oxazina
PE20131394A1 (es) Monohidrato de derivados de aza-adamantano
PE20140337A1 (es) Nuevas formas cristalinas de la sal sodica del acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclhexil)-acetico
NO20083201L (no) Nye fenantridinderivater som bradykininantagonister
PE20160746A1 (es) Composicion farmaceutica que comprende aleglitazar
PE20091560A1 (es) Comprimido de desintegracion oral
MY157492A (en) Pharmaceutical composition 271
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.

Legal Events

Date Code Title Description
FB Suspension of granting procedure